{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:33:41Z","timestamp":1764732821236,"version":"3.37.3"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.parkreldis.2019.08.009","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T11:17:04Z","timestamp":1565608624000},"page":"267-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Drug induced parkinsonism: Symptomatic beyond 22 months"],"prefix":"10.1016","volume":"66","author":[{"given":"Jaskaren","family":"Randhawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.parkreldis.2019.08.009_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/00207454.2012.732976","article-title":"Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?","volume":"123","author":"Lim","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2019.08.009_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00127893-200211000-00006","article-title":"Drug-induced parkinsonism","volume":"8","author":"Van Gerpen","year":"2002","journal-title":"The Neurologist"},{"issue":"8","key":"10.1016\/j.parkreldis.2019.08.009_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.parkreldis.2014.05.011","article-title":"Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations","volume":"20","author":"Brigo","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.08.009_bib4","first-page":"29","article-title":"The impact of DaTscan on the diagnosis and management of movement disorders: a retrospective study","volume":"2","author":"Seifert","year":"2013","journal-title":"Am. J. Neurodegener. Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.08.009_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"Shina","year":"2012","journal-title":"J. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.08.009_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00259-009-1289-4","article-title":"Clinical features and 123 I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease","volume":"37","author":"Diaz-Corrales","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019303657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019303657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T03:46:06Z","timestamp":1570074366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019303657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":6,"alternative-id":["S1353802019303657"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.08.009","relation":{},"ISSN":["1353-8020"],"issn-type":[{"type":"print","value":"1353-8020"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug induced parkinsonism: Symptomatic beyond 22 months","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}